What Clinical Trials Show for Weight Loss
Mounjaro (tirzepatide) edges out Ozempic (semaglutide) for weight loss in head-to-head trials. In the SURMOUNT-5 study, Mounjaro users lost 20.2% of body weight on average after 72 weeks, compared to 13.7% for Ozempic users at similar doses.[1] Both drugs suppress appetite via GLP-1 receptor agonism, but Mounjaro adds GIP receptor activation, which boosts fat metabolism and insulin response more effectively.[2]
Average Weight Loss by Dose and Duration
- Ozempic (weekly injections, max 2.4 mg): 12-15% body weight loss at 68-72 weeks in STEP trials (e.g., 14.9% at 2.4 mg).[3]
- Mounjaro (weekly injections, max 15 mg): 15-22% body weight loss at 72 weeks in SURMOUNT trials (e.g., 20.9% at 15 mg).[4]
Real-world data from electronic health records aligns, with Mounjaro averaging 1-2% more loss than Ozempic over 6-12 months.[5] Losses plateau after 1 year; maintenance requires ongoing use.
Side Effects and Who Tolerates What
Both cause nausea, vomiting, diarrhea, and constipation (20-40% of users), but Mounjaro's dual action leads to slightly higher GI issues early on—though they fade faster.[1][6] Ozempic has more reports of gallbladder problems and retinopathy risks in diabetics.[7] Mounjaro suits those with insulin resistance better due to GIP effects, while Ozempic may be gentler for heart patients (proven CV benefits).[8]
Dropout rates are similar (7-10%), but Mounjaro's higher doses amplify risks like dehydration or pancreatitis (rare, <1%).[4]
Cost and Access Comparison
Ozempic lists at $936/month; Mounjaro at $1,069/month without insurance.[9] Compounded versions (semaglutide ~$200-400/month) mimic Ozempic but lack FDA approval and carry contamination risks.[10] Insurance covers both for diabetes, but weight loss use often requires prior authorization—Mounjaro faces more denials due to newer status.[11]
| Factor | Ozempic | Mounjaro |
|--------|---------|----------|
| Monthly Cost (list) | $936 | $1,069 |
| Insurance for Weight Loss | Variable | Often stricter |
| Supply Shortages | Ongoing | Improving |
Who Should Pick Which—and Alternatives
Choose Mounjaro if max weight loss is the goal and you tolerate GI side effects; opt for Ozempic if cost, heart protection, or familiarity matters. Neither is FDA-approved solely for weight loss—Wegovy (higher-dose Ozempic) or Zepbound (higher-dose Mounjaro) are.[12] Alternatives like oral Rybelsus (semaglutide) lose less (8-10%) but skip needles.[13]
Consult a doctor; factors like BMI >30, comorbidities, and pregnancy plans decide suitability. Long-term data beyond 2 years is limited.
Sources
[1] NEJM: SURMOUNT-5 Trial (2024)
[2] Nature Medicine: Tirzepatide Mechanism
[3] NEJM: STEP 1 Trial
[4] NEJM: SURMOUNT-1 Trial
[5] JAMA: Real-World GLP-1 Study (2024)
[6] FDA: Mounjaro Label
[7] FDA: Ozempic Label
[8] NEJM: SELECT Trial (CV Outcomes)
[9] GoodRx Pricing (Oct 2024)
[10] FDA: Compounded Warnings
[11] KFF: Coverage Trends
[12] FDA: Weight Loss Approvals
[13] NEJM: Oral Semaglutide Trial